BI
ABOS icon

BVF Inc’s Acumen Pharmaceuticals ABOS Stock Holding History

BVF Inc’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-289,663
Closed -$1.13M – 80
2022
Q1 		$1.13M Hold
289,663
– – 0.05% 78
2021
Q4 		$1.96M Hold
289,663
– – 0.07% 78
2021
Q3 		$4.3M Buy
+289,663
New +$4.82M 0.17% 71

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GPC
Guardian Point Capital Charlottesville, Virginia $243M AUM 22.43% 1-Year Est. Return

BVF Inc's ABOS Position: Q2 2022 in Review

BVF Inc sold out of Acumen Pharmaceuticals (ABOS) in Q2 2022, closing a stake of 289,663 shares — an estimated $1.13M sold.

BVF Inc first reported a position in ABOS in Q3 2021 and held it in 3 quarters. The position peaked at $4.3M in Q3 2021. 47 funds tracked by Wall St. Rank hold ABOS as of Q2 2022.

  • BVF Inc reported no remaining Acumen Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • BVF Inc sold 289,663 Acumen Pharmaceuticals shares in Q2 2022, an estimated $1.13M.
  • BVF Inc first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • BVF Inc's Acumen Pharmaceuticals position peaked at $4.3M in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2022.

Based on BVF Inc's 13F filing for Q2 2022, filed 15 Aug 2022.